Avera Pharmaceuticals, Inc. Completes Successful Phase 2 Study Of Gantacurium Chloride For Endotracheal Intubation
6/27/2006 12:10:50 PM
SAN DIEGO--(BUSINESS WIRE)--June 27, 2006--Avera Pharmaceuticals, Inc., a privately held pharmaceutical company developing medicines that act on the nervous system, today announced the successful completion of a Phase 2 clinical study of gantacurium chloride as an adjunct to general anesthesia to enable rapid intubation of patients undergoing surgery. Gantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker.
comments powered by